Aaron Gerds, MD, discusses results of a phase II trial examining the safety and efficacy of luspatercept as a treatment for anemia in patients with myelofibrosis.
Aaron Gerds, MD, MS
Advertisement
Aaron Gerds, MD, is an assistant professor of Medicine (Hematology and Medical Oncology) at the Cleveland Clinic Taussig Cancer Institute in Ohio.
Articles by Aaron Gerds, MD, MS
Aaron Gerds, MD, discusses the adverse event anemia in patients with myelofibrosis.
Aaron Gerds, MD, discusses the future treatment of patients with myeloproliferative neoplasms through the use of JAK-STAT pathway.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
2
As ADC Options Expand, Sequencing and Toxicity Management Become the Next Challenges in Gynecologic Oncology
3
MANGROVE Trial Shows Improved Efficacy With Zanubrutinib Plus Rituximab vs Chemo in MCL
4
Epcoritamab Plus Lenalidomide Improves PFS vs R-GemOx in R/R DLBCL
5